GPER1 and breast carcinoma: By using an immunohistochemical-based approach in breast carcinomas, Filardo and coworkers originally demonstrated that the expression of GPER correlates with clinical and pathological biomarkers of poor outcome as HER-2, increased tumor size and metastasis (59).